Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 11:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 318 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Accepts healthy volunteers

Safety of Graded-Dose of Histidine in Humans

NCT04142294
Conditions
Healthy
Interventions
Histidine
Dietary Supplement
Lead sponsor
Cornell University
Other
Eligibility
21 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ithaca, New York
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Methionine and Cysteine Restriction in Healthy Adults

NCT02192437
Conditions
Healthy
Interventions
Sulfur amino acid restricted diet
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
24 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
State College, Pennsylvania
Conditions
Cystic Fibrosis
Interventions
Tedizolid PO, Tedizolid IV
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Conditions
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Interventions
AMO959, AAA617, Enzalutamide, Abiraterone
Drug · Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Los Angeles, California • El Paso, Texas • Murray, Utah
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
21
States / cities
Newport Beach, California • Bradenton, Florida • Gainesville, Florida + 16 more
Conditions
Bipolar Disorder, Depression
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
44
States / cities
Little Rock, Arkansas • Costa Mesa, California • Escondido, California + 39 more
Conditions
Abdominal Obesity, Hypertension
Interventions
Carvedilol CR + Lisinopril, Lisinopril + HCTZ
Drug
Lead sponsor
St. Paul Heart Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Healthy
Interventions
AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Miami, Florida
Conditions
Crohn's Disease, Active, Crohn's Disease (CD), Diet Interventions
Interventions
Catered Anti-Inflammatory Diet, Diet Guidance for Usual Diet
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
16 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Miami, Florida
Conditions
Leukemia
Interventions
Heavy Water (2H2O), PCI-32765
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
COVID-19, SARS-CoV 2
Interventions
10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Completed Not applicable Interventional Accepts healthy volunteers Results available

Combination Versus Laser Treatment Only

NCT03661697
Conditions
Photoaging
Interventions
Laser Therapy, Basic Skin Care Regimen, Lytera
Device · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Conditions
Malaria
Interventions
Primaquine, R-Primaquine, S-Primaquine, SR Primaquine
Drug
Lead sponsor
University of Mississippi, Oxford
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Oxford, Mississippi
Conditions
Non Small Cell Lung Cancer
Interventions
CMP-001, Atezolizumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Gilbert, Arizona • Duarte, California • Aurora, Colorado + 2 more
Conditions
X Linked Myotubular Myopathy
Interventions
ApoTamox 10mg, Placebo
Drug
Lead sponsor
James Dowling
Other
Eligibility
6 Months and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Rockville, Maryland
Completed Phase 2 Interventional Results available

A Study of TAK-071 in People With Parkinson Disease

NCT04334317
Conditions
Parkinson Disease, Healthy Participants
Interventions
TAK-071, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
40 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
21
States / cities
Garden Grove, California • Irvine, California • Los Angeles, California + 18 more
Conditions
Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
Interventions
Valsartan 80 mg bid, Enalapril 10 mg bid, Sacubitril-Valsartan 200 mg bid, Icatibant, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Single Dose Study of LY3023703 in Healthy Participants

NCT01632579
Conditions
Healthy Volunteers
Interventions
LY3023703, Placebo, Celecoxib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Evansville, Indiana
Not listed Phase 2 Interventional

Catamenial Epilepsy Treatment

NCT01299870
Conditions
Epilepsy
Interventions
AED treatment plus placebo, Keishibukuryogan
Drug
Lead sponsor
Timothy Welty, PharmD
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Post-Traumatic Stress Disorders
Interventions
Eszopiclone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting Not applicable Interventional

Apathy in Parkinson Disease TMS Study

NCT06087926
Conditions
Parkinson Disease
Interventions
Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
55 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Spinal Cord Injury
Interventions
Non-FES Upper Extremity Exercise, RT300-SLSA, from Restorative Therapies, Inc.
Device
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Niemann-Pick Disease, Type C
Interventions
IB1001
Drug
Lead sponsor
IntraBio Inc
Industry
Eligibility
6 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart, Insulin glulisine, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Escondido, California • La Jolla, California • San Mateo, California + 16 more